Ruffer LLP’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-6,918
Closed -$850K 203
2025
Q4
$850K Sell
6,918
-175,425
-96% -$21.3M 0.04% 138
2025
Q3
$20.2M Buy
182,343
+137,246
+304% +$15.6M 1.13% 28
2025
Q2
$5M Buy
+45,097
New +$4.8M 0.22% 64
2025
Q1
Sell
-70,399
Closed -$6.5M 108
2024
Q4
$6.5M Buy
+70,399
New +$6.34M 0.23% 55
2018
Q3
Sell
-12,735
Closed -$902K 79
2018
Q2
$902K Sell
12,735
-81
-0.6% -$5.72K 0.03% 63
2018
Q1
$936K Sell
12,816
-578
-4% -$45.9K 0.05% 51
2017
Q4
$959K Sell
13,394
-455
-3% -$34.6K 0.04% 54
2017
Q3
$1.12M Sell
13,849
-13,146
-49% -$1.01M 0.05% 44
2017
Q2
$1.91M Buy
26,995
+272
+1% +$18.1K 0.09% 35
2017
Q1
$1.78M Sell
26,723
-570,453
-96% -$40.1M 0.11% 38
2016
Q4
$43M Sell
597,176
-308,139
-34% -$22.9M 2.55% 13
2016
Q3
$70.5M Sell
905,315
-71,443
-7% -$5.8M 4.21% 9
2016
Q2
$81.5M Sell
976,758
-8,606
-0.9% -$764K 3.69% 8
2016
Q1
$90.5M Buy
985,364
+133,508
+16% +$12M 3.78% 8
2015
Q4
$86.2M Sell
851,856
-1,197,111
-58% -$125M 3.78% 9
2015
Q3
$201M Buy
2,048,967
+975,225
+91% +$108M 8.6% 4
2015
Q2
$126M Buy
1,073,742
+897,624
+510% +$98.1M 5.48% 8
2015
Q1
$17.3M Buy
+176,118
New +$17.9M 0.75% 22

Other funds holding GILD

Ruffer LLP's GILD Position: Q1 2026 in Review

Ruffer LLP sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 6,918 shares — an estimated $850K sold.

Ruffer LLP first reported a position in GILD in Q1 2015 and held it in 18 quarters. The position peaked at $201M in Q3 2015. 2,320 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Ruffer LLP reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • Ruffer LLP sold 6,918 Gilead Sciences shares in Q1 2026, an estimated $850K.
  • Ruffer LLP first reported a position in Gilead Sciences in Q1 2015 and held it in 18 quarters.
  • Ruffer LLP's Gilead Sciences position peaked at $201M in Q3 2015.
  • 2,320 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Ruffer LLP's 13F filing for Q1 2026, filed 13 May 2026.